BioSpace News Archive

Cidara Therapeutics, Inc. announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 17,000 shares of its common stock to three new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a grant date of December 31, 2021.

Solid Biosciences Inc. today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:00 am ET.

Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI ® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17.

Anokion SA today reported progress for its clinical-stage programs, KAN-101 and ANK-700.

Alumis, formerly Esker Therapeutics, today announced the completion of a $200 million financing led by AyurMaya, an affiliate of Matrix Capital Management, and by a U.S.-based healthcare-focused fund.

VBL Therapeutics announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview at the H.C. Wainwright BioConnect Virtual Conference being held on January 10 – 13, 2022.

Twist Bioscience Corporation announced today an agreement with the Broad Institute to make available a whole exome target enrichment panel to enable next-generation sequencing (NGS) in canine genomics research.

Fortress Biotech, Inc. announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the H.C. Wainwright BioConnect Virtual Conference scheduled to take place from Monday, January 10 through Thursday, January 13, 2022.

The T-cell lymphoma market growth has been possible with the rising incidence of lymphoma cancer because of radiation.

The prostate cancer therapeutics market is anticipated to experience significant growth avenues in the upcoming years.